Onconase data

ACEL (Bloomfield, N.J.) reported that the median survival time of 30 patients enrolled in a Phase II trial of Onconase was longer than that found by most other single agents reviewed in the scientific literature.

Median survival time was 7.7 months, compared to 1.9 to 4.8 months with supportive care or placebo, and 4 to 8.5 months in published trials of single-agent chemotherapies. As reported in the International Journal of Oncology, the median survival time with the ribonuclease was longer than that of 19 out of 20 previously published regimens of a single agent, and longer than that found with three-quarters of the trials the company reviewed that had used combination chemotherapy. ...